StemRIM (TYO:4599)
Japan · Delayed Price · Currency is JPY 300.00
+3.00 (1.01%)
At close: Mar 6, 2026
StemRIM Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
45
Market Cap
18.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jul 31, 2025 | - | - | - |
| Jul 31, 2024 | - | - | - |
| Jul 31, 2023 | 2.35B | 2.33B | 10,581.82% |
| Jul 31, 2022 | 22.00M | -1.38B | -98.43% |
| Jul 31, 2021 | 1.40B | -700.00M | -33.33% |
| Jul 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 7.06B |
| RaQualia Pharma | 3.98B |
| ReproCELL | 2.52B |
| Immuno-Biological Laboratories | 1.03B |
| Stella Pharma | 968.00M |
| AnGes | 874.00M |
| CellSeed | 161.00M |
| Nano Holdings | 155.00M |